Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-11-03
2010-06-29
Desai, Anand U (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
07745393
ABSTRACT:
The present invention provides minimalist bZIP proteins having a basic region derived from bHLH proteins fused to a leucine zipper dimerization domain derived from bZIP proteins and methods and uses thereof in the treatment of cancer. The present invention also provides pharmaceutical compositions for treating cancer.
REFERENCES:
patent: 5962271 (1999-10-01), Chenchik
patent: 5962272 (1999-10-01), Chenchik
patent: 6410246 (2002-06-01), Zhu
patent: 6410271 (2002-06-01), Zhu
patent: 2007/0009938 (2007-01-01), Shin
Lajmi et al.,“Short, Hydrophobic, Alanine-Based Proteins based on the Basic Region/Leucine Zipper Protein Motif: Overcoming inclusion body formation and protein aggregation during overexpression, purification, and renaturation”, Protein Expression and Purification 18: 394-403 (2000).
Glover and Harrison, “Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA”, Nature 373: 275-261 (1995).
Grinberg and Kerppola, “Both Max and TFE3 cooperate with Smad proteins to bind the Plasminogen Activator Inhibitor-1 Promoter, but they have opposite effects on transcriptional activity”, The Journal of Biological Chemistry 278(13): 11227-11236 (2003).
“BD Matchmaker™ One-Hybrid Library Construction & Screening Kit”, BD Biosciences Clontech, Clontechniques, Jan. 2003.
Shin, J. A., “bZIP/bHLH hybrid proteins target specific DNA sequences”, The 229thACS National Meeting, 2005, abstract submitted Nov. 2004, San Diego, CA, USA, abstract.
Shin, J. A., et al., “In vivo directed evolution of DNA-binding proteins in yeast”, The 229thACS National Meeting, 2005, abstract submitted Nov. 2004, San Diego, CA, USA, abstract.
Shin, J. A., “A New Protein-DNA Interaction: designed proteins target the E-box”, The 229th ACS National Meeting, 2005, San Diego, CA, USA, poster presentation.
Shin, J. A., “A New Protein-DNA Interaction: designed proteins target the E-box”, Canadian Society of Chemistry Meeting, 2005, Saskatoon, Canada, poster presentation.
Ferré-D'Amaré, A.R., et al., “Structure and function of the b/HLH/Z domain of USF”, The EMBO Journal, 1994, pp. 180-189, vol. 13, No. 1.
Jakoby, M., et al., “bZIP transcription factors inArabidopsis”, Trends in Plant Science, Mar. 2002, pp. 106-111, vol. 7, No. 3.
Nair, S.K. and Burley, S.K., X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA: Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors, Cell, 2003, pp. 193-205, vol. 112.
Lavigne, P., et al., “Insights into the Mechanism of Heterodimerization from the1H-NMR Solution Structure of the c-Myc-Max Heterodimeric Leucine Zipper”, Journal of Molecular Biology, 1998, pp. 165-181, vol. 281.
Ferré-D'Amaré, A.R., et al., “Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain”, Nature, 1993, pp. 38-45, vol. 363.
Selvaraj, S., et al., “Specificity of Protein—DNA Recognition Revealed by Structure-based Potentials: Symmetric/Asymmetric and Cognate/Non-cognate Binding”, Journal of Molecular Biology, 2002, pp. 907-915, vol. 322.
Agre, P., et al., “Cognate DNA Binding Specificity Retained After Leucine Zipper Exchange Between GCN4 and C/EBP”, Science, 1989, pp. 922-926, vol. 246.
Johnson, O.L., and Tracy, M., “Peptide and Protein Drug Delivery”, Encyclopedia of Controlled Drug Delivery, 1999, pp. 816-833, vol. 2.
Wu, C.Y., et al., “The GCN4 motif in a rice glutelin gene is essential for endosperm-specific gene expression and is activated by Opaque-2 in transgenic rice plants”, The Plant Journal, 1998, pp. 673-683, vol. 14, Issue 6.
Kaiser, J., “First Pass at Cancer Genome Reveals Complex Landscape”, Science, 2006, p. 1370, vol. 313.
Lajmi, A.R., “Short, Hydrophobic, Alanine-Based Proteins Based on the Basic Region/Leucine Zipper Protein motif: Overcoming Inclusion Body Formation and Protein Aggregation during Overexpression, Purification, and Renaturation”, Protein Expression and Purification, 2000, pp. 394-403, vol. 18.
Gura, T., “Systems for Identifying New Drugs Are Often Faulty”, Science, 1997, pp. 1041-1042, vol. 278.
Bereskin & Parr LLP
Desai Anand U
Szweras Melanie
LandOfFree
Minimalist bZIP proteins and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Minimalist bZIP proteins and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Minimalist bZIP proteins and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4175455